ArticleFrontiers in pharmacology2026
Combined treatment with
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taraxerol Alleviates Cerebral Ischemia-Reperfusion Induced Inflammation and Ferroptosis via Regulating AKT/NF-κB Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Cerebral ischemia-reperfusion injury disrupts the brain-gut axis, which involves the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-kappa B (NF-κB) pathway and gut microbiota dysregulation. Materials and methods: 144 Sprague-Dawley rats were divided into groups including: sham, model (transient middle cerebral artery occlusion/reperfusion, MCAO/R), and drug-treated groups receiving Results: Compared with either monotherapy, the combined AT-PNS treatment produced greater improvements in neurological function, reduced cerebral infarct volume, preserved blood-brain and intestinal barrier integrity, and attenuated TLR4/MyD88/NF-κB pathway activation. The combination was also associated with partial normalization of cecal microbiota composition, including an increased Firmicutes/Bacteroidota ratio and reduced Proteobacteria abundance. These effects were attenuated but remained detectable under LPS-induced inflammatory challenge. Conclusion: Combined AT-PNS treatment ameliorated brain-gut axis dysfunction after cerebral ischemia-reperfusion injury and showed greater efficacy than either monotherapy in this fixed-dose experimental design. These effects were accompanied by suppression of TLR4/MyD88/NF-κB signaling, improved barrier integrity, and associated changes in gut microbiota composition. Because the present study did not include dose-response matrices, a formal dose-response interaction profile and a causal microbiota-TLR4 mechanism remain to be established in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.